Long-term topical management of psoriasis: the road ahead
Could topicals be the key to long-term control of plaque psoriasis?
In a recent Journal of Dermatological Treatment article1, eight global dermatology experts share their viewpoints on treating psoriasis and outline why they think the role of topicals in long-term management should be reconsidered.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
This content has been developed in collaboration with LEO Pharma A/S who provided some of the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. MAT-36002. Date of preparation October 2020.
When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Related news and insights
UCB, announced that the FDA has informed the Company that they were unable to complete review of the Biologics License Application (BLA) for bimekizumab for the treatment of moderate to severe plaque psoriasis by the Prescription Drug User Fee Action (PDUFA) date of October 15, 2021.
Arcutis Biotherapeutics, Inc. announced it has submitted a new drug application (NDA) to the FDA for roflumilast cream for the treatment of mild-to-severe plaque psoriasis.